tirzepatide news today recency 3 FDA approves to treat sleep apnea tirzepatide news today recency 3

Targeting APOC3 in the familial chylomicronemia syndrome

Evidence-based medicine advances not only through clinical trials but also through careful observation of real-world patient experiences

AgRP, agouti-related peptide

One of the biggest misconceptions is that you can target the area of the body where you want to lose fat, says Leanna Ross, PhD, an assistant professor of medicine at Duke University School of Medicine and a researcher at Dukes Molecular Physiology Institute

Starting with the right dose and adjusting it thoughtfully over time can help reduce side effects such as nausea or gastrointestinal discomfort, which are common with this type of medication